CYXONE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0942 SEK | +1.51% |
|
+5.84% | -6.18% |
| 22/04 | Sweden's Cyxone Appoints New CEO | MT |
| 22/04 | Cyxone AB Announces Chief Executive Officer Changes | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 20.34M 1.86M 155M |
|---|---|---|---|---|---|
| Net income 2024 * | -28M -2.56M -213M | Net income 2025 * | -38M -3.47M -290M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 1M 91.38K 7.62M | Net cash position 2025 * | 41M 3.75M 313M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-0.52
x | Employees | 3 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.97% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.51% | ||
| 1 week | +5.84% | ||
| Current month | +14.18% | ||
| 1 month | +14.18% | ||
| 3 months | -19.35% | ||
| 6 months | -47.32% | ||
| Current year | -6.18% |
1 week
0.09
0.10
1 month
0.080.11
Current year
0.080.15
1 year
0.080.78
3 years
0.086.50
5 years
0.0810.10
10 years
0.0814.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 20/21/20 | |
| Founder | 58 | 01/15/01 | |
Malin Lindskog
DFI | Director of Finance/CFO | 63 | 15/23/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 58 | 01/15/01 | |
| Director/Board Member | 58 | 01/15/01 | |
Michael Oredsson
CHM | Chairman | 64 | 01/23/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.0942 | +1.51% | 429,976 |
| 26/24/26 | 0.0928 | -4.33% | 1,153,305 |
| 25/24/25 | 0.097 | +1.89% | 522,086 |
| 24/24/24 | 0.0952 | +4.62% | 1,044,945 |
| 23/24/23 | 0.091 | +2.25% | 133,028 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 08:43 pm IST
More quotes
Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.
Sector
Pharmaceuticals
Calendar
17/05/2024
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.18% | 1.83M | |
| +4.06% | 70.44B | |
| +12.64% | 8.94B | |
| -14.44% | 4.75B | |
| +41.60% | 4.5B | |
| +5.96% | 3.85B | |
| +23.46% | 2.38B | |
| -19.32% | 2.34B | |
| -27.04% | 2.2B | |
| +7.97% | 1.96B |
- Stock Market
- Equities
- CYXO Stock
